BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...

Related Keywords

California ,United States ,Lisa Guiterman ,Stacy Lindborg ,Chaim Lebovits ,Prnewswire Brainstorm Cell Therapeutics Inc ,Brainstorm Cell Therapeutics Inc ,European Medicines Agency ,California Institute For Regenerative Medicine ,National Ms Society ,Nasdaq ,Drug Administration ,Storm Cell Therapeutics ,Special Protocol Assessment ,Chief Executive Officer ,Protocol Assessment ,Floor Effect ,Orphan Drug ,California Institute ,Regenerative Medicine ,Regarding Forward Looking Statements ,Health Care Amp Hospitals ,Otc ,Mallcap ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,